SOCRA CCRP PRACTICE EXAM (SAMPLE)

STUDY GUIDE

SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://ccrpsocraexam.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. **Which statement is true about the criteria for involving children in greater than minimal risk research with prospect of benefit?**

   A. Benefits do not need to be justified

   B. The relation of anticipated benefit must be favorable compared with alternative approaches

   C. Parental consent isn't necessary

   D. Children's assent isn't considered important

2. **Which regulation dictates that investigators and staff should be adequately trained?**

   A. ICH GCP 5.14.3

   B. ICH GCP 5.18.4

   C. FDA 1572

   D. ICH GCP 5.1.1

3. **One of the scenarios that require financial disclosure is when there is:**

   A. A proprietary interest by the PI in the tested product.

   B. Government funding for the study.

   C. Use of over-the-counter medications.

   D. Testing of generic products.

4. **What is NOT listed as an essential document that needs to be kept before a trial begins?**

   A. Insurance (if applicable)

   B. Screening log

   C. Regulatory authority approval/notification

   D. Lab normal ranges

5. **What FDA guideline lists the basic elements of informed consent?**

   A. 21 U.S.C. 355

   B. 21 CFR 50

   C. 10 CFR 20

   D. 45 CFR 46

6. Sponsors must submit Unanticipated Adverse Device Effects to the FDA within how many working days?

A. 5 working days

B. 7 working days

C. 10 working days

D. 15 working days

7. What items does an investigator commit to when signing an FDA 1572?

A. Only to follow the protocol

B. Personal conduct of the investigation

C. Follow protocol, Comply with FDA reqs, Personally conduct/supervise, Inform subjects, Follow consent and IRB reqs, Report AEs, Read IB, Ensure staff informed

D. Ensure all staff are informed of their obligations only

8. What is included in the Adverse Events section of the protocol?

A. A plan for public relations

B. Safety parameters and adverse event reporting procedures

C. Details about financial support

D. A schedule of assessments

9. Which of the following is NOT a component of the consent process using a short form?

A. Patient/LAR signs long form consent

B. Short form consent document stating all elements have been presented orally

C. Oral presentation of required elements

D. Witness present during presentation

10. What does QC stand for in the context of trial-related activities?

A. Qualitative Control

B. Quantitative Control

C. Quality Control

D. Quick Control

Answers

1. B
2. B
3. A
4. B
5. B
6. C
7. C
8. B
9. A
10. C

Explanations

1. Which statement is true about the criteria for involving children in greater than minimal risk research with prospect of benefit?

A. Benefits do not need to be justified

B. The relation of anticipated benefit must be favorable compared with alternative approaches

C. Parental consent isn't necessary

D. Children's assent isn't considered important

When involving children in research, it is important to consider the level of risk and potential benefits. Benefits do not need to be justified as they always need to outweigh the risks. Parental consent is absolutely necessary as children cannot legally give their consent. Children's assent is also important but not considered as crucial as parental consent. Therefore, the most important consideration is whether the anticipated benefits outweigh the risks and if the chosen approach is favorable compared to alternative methods. This ensures that the research is ethical and in the best interest of the child.

2. Which regulation dictates that investigators and staff should be adequately trained?

A. ICH GCP 5.14.3

B. ICH GCP 5.18.4

C. FDA 1572

D. ICH GCP 5.1.1

All of the options listed refer to different guidelines and regulations related to clinical trials. However, only option B specifically addresses the requirement for adequate training for investigators and staff. Option A discusses the reporting of adverse events, option C refers to the submission of Form FDA 1572, and option D pertains to the qualifications of investigators. Therefore, option B is the most appropriate and relevant answer to the question.

3. One of the scenarios that require financial disclosure is when there is:

A. A proprietary interest by the PI in the tested product.

B. Government funding for the study.

C. Use of over-the-counter medications.

D. Testing of generic products.

A proprietary interest refers to a financial stake or ownership in a product or company. It is important for financial disclosure to occur in this scenario because the researcher may have a bias towards the product being tested, potentially leading to biased results. B, C, and D are incorrect because they do not involve a direct financial interest in the product being tested. While government funding and use of over-the-counter medications may have implications for financial disclosure in other contexts, in regards to this question, they are not the correct answer because they do not directly involve a proprietary interest in the tested product.

4. What is NOT listed as an essential document that needs to be kept before a trial begins?

A. Insurance (if applicable)

B. Screening log

C. Regulatory authority approval/notification

D. Lab normal ranges

The insurance (if applicable), regulatory authority approval/notification, and lab normal ranges are all essential documents that must be kept before a trial begins. These documents are necessary for legal and compliance purposes and to ensure that the trial is conducted ethically and accurately. While a screening log may also be an important document for keeping track of participants and their eligibility for the trial, it is not listed as an essential document and may vary depending on the specific trial protocol. Therefore, the other options are incorrect as they are all necessary documents for the trial, while a screening log is not specifically listed as essential.

5. What FDA guideline lists the basic elements of informed consent?

A. 21 U.S.C. 355

B. 21 CFR 50

C. 10 CFR 20

D. 45 CFR 46

The Food and Drug Administration (FDA) sets guidelines and regulations for medical research involving human subjects to ensure their safety and rights are protected. The basic elements of informed consent, which include information about the study, potential risks and benefits, and the voluntary nature of participation, are outlined in FDA's Code of Federal Regulations (CFR) section titled "Protection of Human Subjects" or 21 CFR 50. This is why option B is the correct answer. Option A, 21 U.S.C. 355, refers to the U.S. Code section about new drug applications, and option C, 10 CFR 20, pertains to radiation protection standards. These have no direct relation to informed consent in medical research. Option D, 45 CFR 46, is the correct code for the Department of Health and Human Services' regulations for human subjects research. However, this code is not

6. Sponsors must submit Unanticipated Adverse Device Effects to the FDA within how many working days?

A. 5 working days

B. 7 working days

C. 10 working days

D. 15 working days

Unanticipated Adverse Device Effects must be reported to the FDA within 10 working days. This is because it is important for the FDA to be informed of any adverse effects that were not predicted or expected, in a timely manner. Option A and B (5 and 7 working days) may not be enough time to properly evaluate and report the situation. Option D (15 working days) may be too long, as the FDA may need to take immediate action to protect the public from further harm. Therefore, option C (10 working days) strikes a balance between prompt reporting and thorough evaluation.

7. What items does an investigator commit to when signing an FDA 1572?

A. Only to follow the protocol

B. Personal conduct of the investigation

C. Follow protocol, Comply with FDA reqs, Personally conduct/supervise, Inform subjects, Follow consent and IRB reqs, Report AEs, Read IB, Ensure staff informed

D. Ensure all staff are informed of their obligations only

When an investigator signs an FDA 1572, they are committing to following the protocol, complying with FDA requirements, personally conducting or supervising the study, informing subjects, following consent and IRB requirements, reporting adverse events, reading the investigator brochure, and ensuring all staff are informed of their obligations. Options A and B only cover a small portion of the commitments an investigator makes when signing an FDA 1572. Option D is incorrect as it only mentions ensuring staff are informed of their obligations, rather than all of the commitments listed in option C.

8. What is included in the Adverse Events section of the protocol?

A. A plan for public relations

B. Safety parameters and adverse event reporting procedures

C. Details about financial support

D. A schedule of assessments

The Adverse Events section of a protocol outlines the safety parameters and procedures for reporting any adverse events that may occur during the study. Option A, a plan for public relations, is unrelated to the purpose of this section and would not be included. Option C, details about financial support, may be included in the protocol but would be addressed in a separate section. Option D, a schedule of assessments, may also be included in the protocol but would be addressed in a different section as well. Therefore, the best and most complete answer is B, as it specifically addresses the purpose of the Adverse Events section.

9. Which of the following is NOT a component of the consent process using a short form?

A. Patient/LAR signs long form consent

B. Short form consent document stating all elements have been presented orally

C. Oral presentation of required elements

D. Witness present during presentation

The other options listed are components of the consent process using a short form. Option B states that all the elements have been presented orally, making it a crucial component of the short form consent process. Option C, the oral presentation of required elements, is also an imperative aspect of obtaining consent using a short form. Lastly, option D highlights the importance of having a witness present during the oral presentation of the required elements. This helps ensure that the patient or their legal representative fully understands and comprehends the information presented before signing the consent form. Therefore, option A is the only option that does not play a role in the components of the consent process using a short form.

10. What does QC stand for in the context of trial-related activities?

A. Qualitative Control

B. Quantitative Control

C. Quality Control

D. Quick Control

Quality Control (QC) refers to the process of ensuring consistency and accuracy in a specific product or service. In the context of trial-related activities, QC involves evaluating and monitoring all aspects of the trial, including study materials, data collection processes, and analysis methods to ensure their quality and reliability. Option A Qualitative Control is not the correct answer because it refers to the evaluation of the quality of data rather than the overall trial process. Option B: Quantitative Control is not the correct answer because it focuses on the use of numerical data and statistical analysis, rather than the quality of the trial as a whole. Option D: Quick Control is not the correct answer because it is not a commonly used term in the context of trial-related activities and does not accurately reflect the purpose of QC.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://ccrpsocraexam.examzify.com

We wish you the very best on your exam journey. You've got this!